CRFA Awards 16 New Grants and Fellowships

Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

Russ Conroy

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

June 19th 2025

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching

PET-Guided Radiotherapy Successfully Manages Lung and Bone Tumors

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

Russ Conroy

Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.

Related Content

Tim Cortese

Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Stephen V. Liu, MD;Joshua K. Sabari, MD

Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Russ Conroy

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

June 19th 2025